Every tablet starts as a powder.
In Episode 2 of It All Starts Here, discover how it becomes a tablet at our Gidy site in France and Servier Anpharm in Poland: blending, granulation, compression, coating and rigorous controls.
But before the tablet or the capsule, there is the active ingredient. Letโs trace the journey back.
Next stop: Normandy, 23 November.
Learn more https://t.co/5UVCS8fJ7n
#PharmaceuticalIndustry #WeAreServier #MovedByYou
๐ Today is #WorldPancreaticCancerDay.
In 2024, around 531,000 people were diagnosed with pancreatic cancer worldwide, and nearly 490,000 died from the disease. Often diagnosed at an advanced stage, pancreatic cancer remains one of the most challenging cancers to treat.
At Servier, we focus our efforts in oncology on cancers with high unmet needs, including pancreatic cancer.
Learn more: https://t.co/VR2WajOnz4
#WPCD #PancreaticCancer #MovedByYou #WeAreServier
A medicineโs journey doesnโt end with its box.ย
In Arklow, Ireland, over 430 employees manufacture and package 52 products, helping medicines reach patients in 100+ countries.
But before the box, thereโs the tablet. Letโs trace the journey back. Next stops: France & Poland.
๐ Next episode: Nov. 20
It all starts here.
Learn more ๐ https://t.co/4xHrr4rdtt
#PharmaceuticalIndustry #WeAreServier #MovedByYou
๐ This #WorldDiabetesDay, letโs #ActEarlyOnDiabetes.
1 in 9 adults lives with diabetes, while 252M remain undiagnosed. Early detection matters.
Thatโs why, at Servier, we are proud to support @IntDiabetesFed in raising awareness: Know the signs. Know your risk. Act now. ๐
At Servier, we are also helping to improve understanding of type 2 diabetes, its risk factors and the importance of prevention. ๐ https://t.co/HPjXG6fE64
#DiabetesAwareness #WeAreServier #MovedByYou
Where does a medicine come from?
6 episodes tracing the chain back, from the box to the molecule. 7 sites, 5 European countries.
First episode on 16 November. It all starts here.
Learn more ๐ https://t.co/EqhiolrtkN
#PharmaceuticalIndustry#WeAreServier#MovedByYou
Attending #BIOEurope? ๐ Letโs meet in Cologne, Nov 9โ11!
Servier teams will be there to connect with innovative companies and explore new collaborations in #Oncology and #Neurology.
๐ค Donโt miss Marine Beurdeley, Global Business Development Lead, Neurology, who will join the panel discussion โNetworks or neurons: Whatโs next in CNS deal making?โ on ๐๏ธ Nov 10, 09:00 - 09:45 am CET and deliver a presentation introducing Servier and our partnering ambitions ๐๏ธ the same day - 10:30 โ 10:45 am CET (Location: Business of Biotech Stage).
Learn more about our partnering strategy ๐ https://t.co/JciBSpb9Fl
#Innovation #Healthcare
#ESMO26 is now over! We were pleased to share the latest in #oncology science ๐งฌ and upโtoโdate education ๐. In line with our #Servier2030 ambition, our #research ๐ฌ is focused on rare #cancers ๐๏ธ to address high unmet medical needs among #patients ๐ฉบ. @myESMOย
Learn more about our commitment to oncology ๐ https://t.co/paITVr2zUx
๐ง International Brain Tumour Awareness Week has begun.
At Servier, we are committed to advancing research in rare cancers, including gliomas, to bring innovative therapeutic solutions to patients who need them most.
Learn more ๐ https://t.co/QbLRhVOlAZ
#BrainTumor#IBTAWeek #BrainTumourAwareness #WeAreServier #MovedByYou
๐ Weโre attending #ESMO26!ย
For over 10 years, #oncology has been our top priority โ close to 70% of our R&D budget is dedicated to advancing cancer research. Today, our pipeline includes 36 projects, with a strong focus on rare #cancers.
Meet us at booth No. 8064 ๐ข and join our symposiums to learn more.
Discover our commitment to oncology ๐ https://t.co/luf0InTwEH
#CancerResearch #patient @myESMO
๐ October is KCNT1 Awareness Month!
At Servier, we proudly support KCNT1 Epilepsy Foundationโs campaign to raise awareness of this rare epilepsy which affects young children
Neurology is now a key focus of our #Servier2030 strategy, with 14 active R&D projects.
๐ https://t.co/lieJh2uKoi
#KCNT1 #Neurology #WeAreServier
Who better to describe life at Servier than the people who live it every day? โจ
Meet Elodie ๐ซ๐ท, one of our 10 career ambassadors selected by colleagues across the Group. In her interview, she shares her journey, what gives meaning to her work, and what keeps her moving forward.
๐ฌ โI care about my mission with passion, we care for patients with innovation.โ
๐ https://t.co/dnIjPkRMRs
#WeAreServier #MovedByYou #CareerStories #CareerJourney
๐ฌ Today on #FragileXAwarenessDay, we reaffirm our commitment to advancing research in rare neurological disorders.
Fragile X syndrome, caused by a change in the FMR1 gene, is one of the leading known genetic causes of autism spectrum disorder and affects ~1 in 7,000 males and 1 in 11,000 females.
At Servier, we aim to become a global leader in rare neuro diseases by 2030 and strengthened this ambition in 2025 with the acquisition of a potential Fragile X treatment.ย
Learn more about Fragile X syndrome ๐ https://t.co/WYZsvDifc3
#WeAreServier #MovedByYou #RareDiseases #Neurology #FragileXSyndrome
๐ฆ๐บ What makes a career meaningful?
For Sarah, itโs the people, experiences and purpose that shape her journey at Servier. As one of our career ambassadors, she shares what drives her forward every day.
๐ฌ โI grow my knowledge every day, we grow hope every step of the way.โ
๐ฅ Discover Sarahโs story: https://t.co/nGFUoI338d
#WeAreServier #MovedByYou #CareerStories #CareerJourney #PurposeAtWork
๐งฌ During #BeckerMuscularDystrophy Awareness Week, we reaffirm our commitment to people living with rare neuromuscular diseases.
Becker muscular dystrophy is one of the areas where significant unmet medical needs remain. we are committed to advancing research in rare neurological disorders and addressing unmet patient needs. At Servier, our ambition is to become a global leader in rare neurological diseases by 2030.ย
Learn more about Becker muscular dystrophy ๐ https://t.co/kygWSylUQ9
#WeAreServier #MovedByYou #RareDisease #Neurology
๐ With @Techoย and the support of Mรฉcรฉnat Servier, 12 emergency houses have been built across Argentina, Brazil, Colombia, Ecuador, Mexico and Panama.
More than shelter, these homes bring safety, dignity and hope to families facing extreme poverty. Built together by volunteers and beneficiary families, they show the power of collective action.
๐ฅ Discover the impact in Brazil and across Latin America: https://t.co/YOOUl6UNoO
#WeAreServier #MovedByYou #MecenatServier #Solidarity
#EANS2026 has come to an end!
We were delighted to connect with the European and international neurosurgical community, share perspectives, and discuss the challenges and opportunities ahead in neuroscience.
In line with our #Servier2030 strategy, we invest close to 70% of our R&D budget in oncology research ๐ฌ, with a particular focus on cancers where significant unmet medical needs remain.
Learn more about our commitment to oncology ๐ https://t.co/mn4AviNRSS
#WeAreServier #MovedByYou #Neuroscience #Neurosurgery @EANSonline50
๐ First time at #WMS2026 in Hiroshima! More than a congress presence, it marks another step in our commitment to the rare neurology community.ย
At Servier, the acquisition of @EdgewiseTx 's Muscular Dystrophy Business strengthens our commitment to rare neurological disorders and advancing innovation for people living with Duchenne and Becker muscular dystrophies.
๐ https://t.co/OWoTI2O7Ql
#WMS2026 #neurology #WeAreServier #MovedByYou
The #EASD2026 Congress is now over! We were pleased to share insights with the global community into advances in #diabetes research and care.
#T2D#innovation#DiabetesCare@EASDnews
๐ Read more about our commitments in diabetes ๐ https://t.co/ystnSMa1vt
๐ฌ โI make an impact with my expertise, we make an impact in rare diseases.โ
What keeps you moving forward in your career?
For Qiang in China ๐จ๐ณ, itโs the opportunity to learn, contribute and make a difference alongside passionate colleagues. As one of our career ambassadors, he shares an authentic perspective on life at Servier.
๐ Read Qiangโs story: https://t.co/POdNwf4OkE
#WeAreServier #MovedByYou #CareerStories #CareerJourney